DE69516524D1 - Therapeutisch verwendbare spiro-azabicyclische verbindungen - Google Patents

Therapeutisch verwendbare spiro-azabicyclische verbindungen

Info

Publication number: DE69516524D1
Authority: DE; Germany
Prior art keywords: spiro; azabicyclic compounds; therapeutically applicable; therapeutically; applicable
Prior art date: 1994-08-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69516524T

Other languages

English (en)

Other versions

DE69516524T2 (de

Inventor

Michael Balestra

Charles Gordon

Conrad Griffith

John Murray

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AstraZeneca AB

Original Assignee

Astra AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-24

Filing date

1995-08-22

Publication date

2000-05-31

1994-08-24 Priority claimed from GB9417084A external-priority patent/GB9417084D0/en

1995-03-08 Priority claimed from GBGB9504627.2A external-priority patent/GB9504627D0/en

1995-08-22 Application filed by Astra AB filed Critical Astra AB

2000-05-31 Publication of DE69516524D1 publication Critical patent/DE69516524D1/de

2001-01-18 Application granted granted Critical

2001-01-18 Publication of DE69516524T2 publication Critical patent/DE69516524T2/de

2015-08-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DE69516524T 1994-08-24 1995-08-22 Therapeutisch verwendbare spiro-azabicyclische verbindungen Expired - Fee Related DE69516524T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9417084A GB9417084D0 (en)	1994-08-24	1994-08-24	Compounds useful in therapy
GBGB9504627.2A GB9504627D0 (en)	1995-03-08	1995-03-08	Compounds for use in therapy
PCT/SE1995/000937 WO1996006098A1 (en)	1994-08-24	1995-08-22	Spiro-azabicyclic compounds useful in therapy

Publications (2)

Publication Number	Publication Date
DE69516524D1 true DE69516524D1 (de)	2000-05-31
DE69516524T2 DE69516524T2 (de)	2001-01-18

Family

ID=26305509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69516524T Expired - Fee Related DE69516524T2 (de)	1994-08-24	1995-08-22	Therapeutisch verwendbare spiro-azabicyclische verbindungen

Country Status (33)

Country	Link
US (2)	US5902814A (de)
EP (1)	EP0777671B1 (de)
JP (1)	JP3708962B2 (de)
KR (1)	KR100366331B1 (de)
CN (2)	CN1056846C (de)
AR (1)	AR031828A2 (de)
AT (1)	ATE192157T1 (de)
AU (1)	AU690735B2 (de)
BR (1)	BR9508751A (de)
CA (1)	CA2196995C (de)
CZ (1)	CZ289512B6 (de)
DE (1)	DE69516524T2 (de)
DK (1)	DK0777671T3 (de)
EE (1)	EE03399B1 (de)
EG (1)	EG24222A (de)
ES (1)	ES2145922T3 (de)
FI (1)	FI112868B (de)
GR (1)	GR3033878T3 (de)
HU (1)	HUT77352A (de)
IL (1)	IL115039A (de)
IS (1)	IS1852B (de)
MX (1)	MX9701292A (de)
NO (1)	NO307707B1 (de)
NZ (1)	NZ292289A (de)
PL (1)	PL183933B1 (de)
PT (1)	PT777671E (de)
RU (1)	RU2148058C1 (de)
SA (1)	SA95160370B1 (de)
SK (1)	SK282366B6 (de)
TR (1)	TR199501053A2 (de)
TW (1)	TW397837B (de)
UA (1)	UA54375C2 (de)
WO (1)	WO1996006098A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5977144A (en) *	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AR013184A1 (es) *	1997-07-18	2000-12-13	Astrazeneca Ab	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) *	1998-05-04	2001-08-21	Astra Ab	Use
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
JP4564135B2 (ja) *	1999-07-26	2010-10-20	住友化学株式会社	高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
AU2001241056A1 (en) *	2000-03-09	2001-09-17	Mitsubishi Pharma Corporation	Spiro compounds, process for preparing the same and use thereof as drugs
US8914114B2 (en)	2000-05-23	2014-12-16	The Feinstein Institute For Medical Research	Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2421309A1 (en) *	2000-08-28	2002-03-07	Colorado State University Research Foundation	Compounds containing oxazolidinone moiety and uses thereof
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20040259909A1 (en) *	2001-10-16	2004-12-23	Mccarthy Dennis	Treatment of fibromyalgia syndrome
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
US20040048795A1 (en) *	2002-02-26	2004-03-11	North Shore-Long Island Jewish Research Institute	Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
SE0202598D0 (sv) *	2002-09-02	2002-09-02	Astrazeneca Ab	Alpha-7 Nicotinic receptor agonists and statins in combination
CN102657651A (zh)	2002-12-06	2012-09-12	范因斯坦医学研究院	用α 7受体结合胆碱能激动剂抑制炎症
US7238715B2 (en) *	2002-12-06	2007-07-03	The Feinstein Institute For Medical Research	Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
MXPA06000231A (es) *	2003-07-08	2006-04-11	Astrazeneca Ab	Derivados espiro '1-azabiciclo'2.2.2!octan-3,5'-oxazolidin-2'-ona! con afinidad a la alfa7 del receptor nicotinico para acetilcolina.
WO2005092308A2 (en) *	2004-03-25	2005-10-06	The Feinstein Institute For Medical Research	Neural tourniquet
US10912712B2 (en)	2004-03-25	2021-02-09	The Feinstein Institutes For Medical Research	Treatment of bleeding by non-invasive stimulation
WO2006065209A1 (en) *	2004-12-15	2006-06-22	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
CA2593079C (en)	2004-12-27	2014-08-19	North Shore-Long Island Jewish Research Institute	Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en)	2004-12-27	2021-12-28	The Feinstein Institutes For Medical Research	Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1833804A1 (de) *	2004-12-28	2007-09-19	AstraZeneca AB	Arylsulfonamidmodulatoren
EP2275095A3 (de) *	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
RU2326787C2 (ru) *	2005-11-09	2008-06-20	Сергей Федорович Бокарев	Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления
US8316104B2 (en)	2005-11-15	2012-11-20	California Institute Of Technology	Method and apparatus for collaborative system
EP2255848A3 (de)	2006-09-04	2011-04-06	NeuroSearch AS	Pharmazeutische Kombinationen von Nicotin Rezeptor Modulatoren und Agenzien zur Verbesserung der kognitiven Fähigkeiten
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US8391970B2 (en)	2007-08-27	2013-03-05	The Feinstein Institute For Medical Research	Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102008015999B4 (de)	2008-03-27	2011-04-21	Novar Gmbh	Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage
US9662490B2 (en)	2008-03-31	2017-05-30	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) *	2008-03-31	2009-12-03	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US8309577B2 (en)	2008-04-23	2012-11-13	Bristol-Myers Squibb Company	Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) *	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
EP2307389B1 (de)	2008-06-20	2013-01-23	AstraZeneca AB	Dibenzothiazepinderivat und anwendung davon
WO2010059617A2 (en)	2008-11-18	2010-05-27	Setpoint Medical Corporation	Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
AU2009316557B2 (en)	2008-11-19	2015-08-27	Envivo Pharmaceuticals, Inc.	Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en)	2009-05-01	2015-12-15	Setpoint Medical Corporation	Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en)	2009-10-30	2015-03-31	Setpoint Medical Corporation	Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
BRPI1014793A2 (pt) *	2009-05-11	2016-04-05	Envivo Pharmaceuticals Inc	tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
WO2010144578A2 (en)	2009-06-09	2010-12-16	Setpoint Medical Corporation	Nerve cuff with pocket for leadless stimulator
EP2493894B1 (de)	2009-10-28	2014-01-29	Bristol-Myers Squibb Company	Ayabicyclische verbindungen als alpha-7-nikotin-acetylcholin-rezpetorliganden
US8278320B2 (en)	2009-10-28	2012-10-02	Bristol-Myers Squibb Company	Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9833621B2 (en)	2011-09-23	2017-12-05	Setpoint Medical Corporation	Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en)	2013-04-10	2014-10-16	Setpoint Medical Corporation	Closed-loop vagus nerve stimulation
CN102821814B (zh)	2009-12-23	2015-07-15	赛博恩特医疗器械公司	用于治疗慢性炎症的神经刺激设备和系统
CN103025744A (zh)	2010-04-30	2013-04-03	百时美施贵宝公司	作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
CA2799744C (en)	2010-05-17	2020-01-28	Envivo Pharmaceuticals, Inc.	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012154865A2 (en)	2011-05-09	2012-11-15	Setpoint Medical Corporation	Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en)	2011-05-09	2024-12-24	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
GB201111705D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Compounds and their use
GB201111704D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Novel compounds
JO3115B1 (ar)	2011-08-22	2017-09-20	Takeda Pharmaceuticals Co	مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en)	2012-03-26	2017-02-21	Setpoint Medical Corporation	Devices and methods for modulation of bone erosion
US9585877B2 (en)	2012-05-08	2017-03-07	Forum Pharmaceuticals, Inc.	Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en)	2012-05-30	2012-07-11	Takeda Pharmaceutical	Therapeutic compounds
JP6478923B2 (ja)	2013-02-07	2019-03-06	ヘプタレスセラピューティクスリミテッドＨｅｐｔａｒｅｓＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
EA029430B1 (ru)	2013-06-21	2018-03-30	Такеда Фармасьютикл Компани Лимитед	Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en)	2013-08-08	2013-09-25	Takeda Pharmaceutical	Therapeutic Compounds
GB201318222D0 (en)	2013-10-15	2013-11-27	Takeda Pharmaceutical	Novel compounds
GB201320905D0 (en)	2013-11-27	2014-01-08	Takeda Pharmaceutical	Therapeutic compounds
TW201613864A (en)	2014-02-20	2016-04-16	Takeda Pharmaceutical	Novel compounds
US11311725B2 (en)	2014-10-24	2022-04-26	Setpoint Medical Corporation	Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en)	2015-02-03	2016-08-11	Setpoint Medical Corporation	Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en)	2016-01-13	2020-03-24	Setpoint Medical Corporation	Systems and methods for establishing a nerve block
US11471681B2 (en)	2016-01-20	2022-10-18	Setpoint Medical Corporation	Batteryless implantable microstimulators
WO2017127758A1 (en)	2016-01-20	2017-07-27	Setpoint Medical Corporation	Implantable microstimulators and inductive charging systems
CN114904142A (zh)	2016-01-20	2022-08-16	赛博恩特医疗器械公司	迷走神经刺激的控制
US10583304B2 (en)	2016-01-25	2020-03-10	Setpoint Medical Corporation	Implantable neurostimulator having power control and thermal regulation and methods of use
US10661112B2 (en)	2016-07-25	2020-05-26	Tonal Systems, Inc.	Digital strength training
US11745039B2 (en)	2016-07-25	2023-09-05	Tonal Systems, Inc.	Assisted racking of digital resistance
GB201616839D0 (en)	2016-10-04	2016-11-16	Takeda Pharmaceutical Company Limited	Therapeutic compounds
GB201619514D0 (en)	2016-11-18	2017-01-04	Takeda Pharmaceuticals Co	Novel compounds
EP3668402B1 (de)	2017-08-14	2024-07-31	Setpoint Medical Corporation	Vagusnervstimulationsvorscreening-test
US10486015B2 (en)	2017-10-02	2019-11-26	Tonal Systems, Inc.	Exercise machine enhancements
US10589163B2 (en)	2017-10-02	2020-03-17	Tonal Systems, Inc.	Exercise machine safety enhancements
US10617903B2 (en)	2017-10-02	2020-04-14	Tonal Systems, Inc.	Exercise machine differential
US10335626B2 (en)	2017-10-02	2019-07-02	Tonal Systems, Inc.	Exercise machine with pancake motor
US11660443B2 (en)	2018-04-20	2023-05-30	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en)	2018-09-25	2022-03-01	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en)	2019-04-12	2025-11-20	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
JP2021138648A (ja)	2020-03-04	2021-09-16	武田薬品工業株式会社	経口固形製剤
US11938324B2 (en)	2020-05-21	2024-03-26	The Feinstein Institutes For Medical Research	Systems and methods for vagus nerve stimulation
US11285355B1 (en)	2020-06-08	2022-03-29	Tonal Systems, Inc.	Exercise machine enhancements
US11998804B2 (en)	2021-04-27	2024-06-04	Tonal Systems, Inc.	Repetition phase detection
US11878204B2 (en)	2021-04-27	2024-01-23	Tonal Systems, Inc.	First repetition detection
WO2022245878A1 (en)	2021-05-17	2022-11-24	Setpoint Medical Corporation	Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH601304A5 (de) *	1974-02-12	1978-07-14	Buskine Sa
US4028351A (en) *	1971-09-07	1977-06-07	Buskine S.A.	Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained
SU495310A1 (ru) *	1974-03-05	1975-12-15	Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе	Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
GB8808433D0 (en) *	1988-04-11	1988-05-11	Merck Sharp & Dohme	Therapeutic agents
GB8816299D0 (en) *	1988-07-08	1988-08-10	Merck Sharp & Dohme	Therapeutic agents
IL97726A (en) *	1990-04-10	1994-12-29	Israel Inst Biolog Res	Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5534520A (en) *	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
US5073560A (en) *	1990-07-20	1991-12-17	Fisons Corporation	Spiro-isoxazolidine derivatives as cholinergic agents
US5137895A (en) *	1991-04-29	1992-08-11	A. H. Robins Company, Incorporated	3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols

1995
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active Expired - Fee Related
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en not_active Ceased
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 EP EP95930755A patent/EP0777671B1/de not_active Expired - Lifetime
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
1998
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK21697A3 (en)	1997-09-10
EE9700039A (et)	1997-08-15
WO1996006098A1 (en)	1996-02-29
PT777671E (pt)	2000-08-31
PL183933B1 (pl)	2002-08-30
IS1852B (is)	2003-02-21
CZ39297A3 (en)	1997-12-17
BR9508751A (pt)	1997-08-12
CZ289512B6 (cs)	2002-02-13
CA2196995C (en)	2008-05-13
ATE192157T1 (de)	2000-05-15
HUT77352A (hu)	1998-03-30
FI970762L (fi)	1997-02-24
ES2145922T3 (es)	2000-07-16
GR3033878T3 (en)	2000-11-30
FI970762A0 (fi)	1997-02-24
US5902814A (en)	1999-05-11
NO307707B1 (no)	2000-05-15
IL115039A (en)	2001-08-26
PL318760A1 (en)	1997-07-07
HK1010370A1 (en)	1999-06-17
EG24222A (en)	2008-11-10
IL115039A0 (en)	1995-12-08
CN1284505A (zh)	2001-02-21
SA95160370B1 (ar)	2006-06-04
DE69516524T2 (de)	2001-01-18
EE03399B1 (et)	2001-04-16
JP3708962B2 (ja)	2005-10-19
JPH10504561A (ja)	1998-05-06
NO970800D0 (no)	1997-02-21
AU690735B2 (en)	1998-04-30
NZ292289A (en)	1998-05-27
CN1159808A (zh)	1997-09-17
AR031828A2 (es)	2003-10-08
TR199501053A2 (tr)	1996-06-21
SK282366B6 (sk)	2002-01-07
UA54375C2 (uk)	2003-03-17
EP0777671B1 (de)	2000-04-26
CA2196995A1 (en)	1996-02-29
TW397837B (en)	2000-07-11
CN1099419C (zh)	2003-01-22
MX9701292A (es)	1997-05-31
DK0777671T3 (da)	2000-07-24
IS4424A (is)	1997-02-03
EP0777671A1 (de)	1997-06-11
RU2148058C1 (ru)	2000-04-27
US6051581A (en)	2000-04-18
AU3401895A (en)	1996-03-14
KR100366331B1 (ko)	2003-04-10
NO970800L (no)	1997-02-21
FI112868B (fi)	2004-01-30
CN1056846C (zh)	2000-09-27

Publication	Publication Date	Title
DE69516524D1 (de)	2000-05-31	Therapeutisch verwendbare spiro-azabicyclische verbindungen
ATE193298T1 (de)	2000-06-15	Therapeutische verbindungen
DE69616817D1 (de)	2001-12-13	Substituierte benzylaminopiperloin verbindungen
ATE298739T1 (de)	2005-07-15	Calcylitische verbindungen
FI970995L (fi)	1997-04-25	Farmaseuttisia yhdisteitä
FI971018L (fi)	1997-04-18	Farmaseuttisia yhdisteitä
ATE218536T1 (de)	2002-06-15	Entzündungshemmende verbindungen
FI971260A7 (fi)	1997-03-26	1-asyyli-4-alifatyyliaminopiperidiiniyhdisteet
BR9509760A (pt)	1998-06-30	Composto
ID16345A (id)	1997-09-25	Senyawa-senyawa heterosiklik
DE69528825D1 (de)	2002-12-19	Dendrime verbindungen
FI954327L (fi)	1995-09-14	Atsasykloheksapeptidiyhdisteitä
FI961696L (fi)	1996-04-18	Pyridatsinokinoliiniyhdisteitä
DE69617041D1 (de)	2001-12-20	Parasitizide verbindungen
ATE222893T1 (de)	2002-09-15	Triazinylaminostilben verbindungen
FI954243A7 (fi)	1996-03-13	Farmaseuttiset yhdisteet
BR9600251A (pt)	1997-12-23	Composto
EE9800172A (et)	1998-12-15	Ühendid
DE69531522D1 (de)	2003-09-25	Heterozyklische Verbindungen
DK72693D0 (da)	1993-06-18	Compounds
ATE225364T1 (de)	2002-10-15	Bromotiacumicin verbindungen
NO974170D0 (no)	1997-09-09	Polyazacykloalkan-forbindelser
FI970151A0 (fi)	1997-01-14	Viruksenvastaisesti vaikuttavia difluoristatoniyhdisteitä
BR9601295A (pt)	1998-01-13	Composto
DK124393D0 (da)	1993-11-03	Compounds

Legal Events

Date	Code	Title	Description
2000-08-31	8327	Change in the person/name/address of the patent owner	Owner name: ASTRAZENECA AB, SOEDERTAELJE, SE
2001-05-17	8364	No opposition during term of opposition
2010-06-24	8339	Ceased/non-payment of the annual fee